Sumitomo Pharma Co

Sumitomo Pharma Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Sumitomo Pharma Co (4506.T) as of Nov 4, 2026 is 62.80 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 33.86 % — a change of 85.47% (higher).

FCF Conversion

62.80 %

YoY

85.47%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Sumitomo Pharma Co is 2026 62.80 % . FCF Conversion Rate (FCF/EBITDA) of Sumitomo Pharma Co was 2025 33.86 % . It decreases by 85.47% higher compared to the previous year.

The Sumitomo Pharma Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
81.12 JPY
Jan 1, 2020
80.43 JPY
Jan 1, 2021
221.98 JPY
Jan 1, 2022
31.46 JPY
Jan 1, 2023
1.08 JPY
Jan 1, 2024
80.22 JPY
Jan 1, 2025
33.86 JPY
Jan 1, 2026
62.80 JPY
The Sumitomo Pharma Co FCF Conversion history
YEARFCF ConversionYoY
62.80 %+85.47%
33.86 %-57.79%
80.22 %+7,325.16%
1.08 %-96.57%
31.46 %-85.83%
221.98 %+176.00%
80.43 %-0.85%
81.12 %-50.89%
165.19 %+369.77%
35.16 %-81.56%
190.73 %+23.47%
154.47 %-21.77%
197.46 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sumitomo Pharma Co Stock analysis

What does Sumitomo Pharma Co do? Sumitomo Dainippon Pharma Co Ltd is a biopharmaceutical company headquartered in Osaka, Japan. It was originally founded as Dainippon Pharmaceutical Co. Ltd in 1885 and later merged with Sumitomo Pharmaceuticals in 2005 to form the new Sumitomo Dainippon Pharma. The company operates in various areas, such as psychiatric and neurological medicine, oncology, dermatology, and infectious diseases. The products include both prescription and over-the-counter medications. In psychiatric and neurological medicine, Sumitomo Dainippon Pharma offers drugs that can be used to treat depression, anxiety disorders, schizophrenia, and bipolar disorders. One of the most well-known medications in this category is the antipsychotic Latuda, which is used for schizophrenia and bipolar disorder. In oncology, Sumitomo Dainippon Pharma has developed medications that can be used in the treatment of cancers such as lung, liver, pancreatic, colorectal, and blood cancer. The company is also involved in developing treatments for rare forms of cancer and immune-mediated diseases. In dermatology, Sumitomo Dainippon Pharma has developed medications for the treatment of skin and nail infections, psoriasis, and atopic dermatitis. The company is also working on innovative treatment approaches for skin cancer and other types of skin diseases. Sumitomo Dainippon Pharma is also involved in the development of treatments for infectious diseases, including medications for HIV and hepatitis C. The business model of Sumitomo Dainippon Pharma is based on the development of new drugs and the marketing of prescription and over-the-counter medications on a global level. The company focuses on researching and developing drugs that can address significant medical needs and that differentiate themselves from other medications on the market. The products are registered and marketed in various countries, especially in the US and Japan. Sumitomo Dainippon Pharma invests significantly in research and development. The company has R&D sites in Japan, the US, UK, and Ireland. It also collaborates with other companies to leverage innovative technologies and accelerate the development of new medications. Overall, Sumitomo Dainippon Pharma has a long history in the pharmaceutical industry and is committed to creating a wide range of medications and therapies for various diseases and conditions. The company is dedicated to improving the lives of patients and contributing to the well-being of society as a whole. Sumitomo Pharma Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sumitomo Pharma Co stock

FCF Conversion Rate (FCF/EBITDA) of Sumitomo Pharma Co is 62.80 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Sumitomo Pharma Co changed from 33.86 % to 62.80 %, representing a 85.47% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Sumitomo Pharma Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Sumitomo Pharma Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Sumitomo Pharma Co

All Key Metrics — Sumitomo Pharma Co